AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
AGOURON PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS SAN DIEGO, Nov. 1 /PRNewswire/ -- Agouron Pharmaceuticals Inc.
(NASDAQ-NMS: AGPH) today announced a net loss of $2,107,000 or $.43 per common share, on revenues of $1,096,000 for the quarter ended Sept. 30, 1991. The net loss recorded in the comparable period of the prior fiscal year was $1,588,000, or $.37 per common share, on revenues of $1,100,000. Operating results for the first three months of the fiscal year reflect Agouron's continuing investment in proprietary research and development activities.
Agouron Pharmaceuticals Inc. is a pioneer and leader in a new technology for the rational design of novel synthetic drugs based upon the molecular structures of proteins which play key roles in human disease. Agouron is currently applying this technology to the design and development of drugs for treatment of cancer, AIDS, and other serious diseases. AGOURON PHARMACEUTICALS INC. Summary Financial Information Three Months Ended Sept. 30, 1991 1990 Revenues $1,096,000 $1,100,000 Net loss ($2,107,000) ($1,588,000) Net loss per common share ($.43) ($.37) Shares used in computing net loss per common share 4,883,000 4,242,000 -0- 11/1/91 /CONTACT: Steven S. Cowell, vice president & CFO or Donna Nichols, 619-622-3000, of Agouron Pharmaceuticals Inc. (AGPH) CO: Agouron Pharmaceuticals Inc. ST: California IN: MTC SU: ERN EH-KJ -- SD001 -- 0455 11/01/91 18:10 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 1, 1991|
|Previous Article:||MAGMA COPPER CLOSES PURCHASE OF REMAINING INTEREST IN ROBINSON|
|Next Article:||NUVEEN EXCHANGE-TRADED FUNDS DECLARE TAX-FREE DIVIDENDS|